All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec001}
============

Microsporidia comprises 200 genera and nearly 1,500 species of spore-forming parasites ubiquitously found in the environment and able to colonize/infect a wide variety of invertebrate and vertebrate hosts \[[@pntd.0008419.ref001],[@pntd.0008419.ref002]\]. Among the 17 Microsporidia species infecting humans *Enterocytozoon bieneusi* is the most frequently reported, causing gastrointestinal infections globally \[[@pntd.0008419.ref003]\]. Infections with *E*. *bieneusi* in immunocompromised individuals (e.g. patients with AIDS, cancer, organ transplant recipients, and the elderly) are usually associated with chronic diarrhoea, wasting syndrome, and weight loss. Infections in immunocompetent subjects are often asymptomatic or result in self-limited diarrhoea and malabsorption \[[@pntd.0008419.ref004],[@pntd.0008419.ref005]\]. Extraintestinal disorders and pathologies have also been reported, mainly in lung \[[@pntd.0008419.ref006]\]. In addition, *E*. *bieneusi* infection in early childhood has been recently linked to impaired growth in children in low-resource settings including African countries such as Malawi, South Africa, or Tanzania \[[@pntd.0008419.ref007],[@pntd.0008419.ref008]\]. *Enterocytozoon bieneusi* has a high genetic diversity and is capable of colonizing/infecting a broad spectrum of mammal and avian species. There are marked differences in host specificities and zoonotic potential among those genotypes \[[@pntd.0008419.ref009]--[@pntd.0008419.ref011]\]. Infections are acquired through ingestion of food and water contaminated with *E*. *bieneusi* spores, or through direct contact with faeces of infected persons and animals or with contaminated soils \[[@pntd.0008419.ref002],[@pntd.0008419.ref012],[@pntd.0008419.ref013]\].

The highly polymorphic ribosomal internal transcribed spacer (ITS) of the ribosomal rRNA (rRNA) gene is the most widely used marker for assessing the genetic diversity within *E*. *bieneusi* \[[@pntd.0008419.ref011]\]. Based on ITS nucleotide sequences nearly 500 genotypes have been validated according to current nomenclature standards that are distributed into 11 distinct phylogenetic groups \[[@pntd.0008419.ref010],[@pntd.0008419.ref014]\]. Groups 1 and 2 comprise genotypes able to infect a broad range of mammalian species including humans and are, therefore, considered potentially zoonotic. On the other hand, groups 3‒11 have strong host specificities and are considered to pose little or null zoonotic risk \[[@pntd.0008419.ref011]\].

The Global Enteric Multicenter Study (GEMS) has provided important information on the aetiology and population-based burden of paediatric diarrheal diseases in sub-Saharan Africa and South Asia. GEMS included in their study enteric protozoan parasites *Giardia duodenalis*, *Cryptosporidium* spp., and *Entamoeba histolytica*, but not the microsporidia *E*. *bieneusi* \[[@pntd.0008419.ref015]\]. However, in recent years there has been a steady increase in the studies aiming to improve our understanding of the epidemiology of *E*. *bieneusi* in Africa since this parasite is frequently reported in immunocompromised individuals in African countries ([Table 1](#pntd.0008419.t001){ref-type="table"} and [S1 Fig](#pntd.0008419.s001){ref-type="supplementary-material"}). Importantly, early microscopy-based studies documented *E*. *bieneusi* prevalences as high as 40‒67% in apparently healthy people in Cameroon \[[@pntd.0008419.ref016]\] and Nigeria \[[@pntd.0008419.ref017]\]. These findings indicate that asymptomatic, chronic *E*. *bieneusi* infections could be more frequent than anticipated. Despite the undoubted progress achieved over the past years, the actual epidemiological situation of *E*. *bieneusi* in most African countries, including Mozambique, remains largely unknown. To fill this gap, the present study aims to investigate the occurrence and genetic diversity of *E*. *bieneusi* in symptomatic and asymptomatic paediatric populations in two of the most populous provinces of Central (Zambézia) and Southern (Maputo) Mozambique.

10.1371/journal.pntd.0008419.t001

###### *Enterocytozoon bieneusi* infections reported in humans in African countries including country of origin, type of surveyed population, symptomatology, diagnostic method, and reported prevalence and genotypes.

Diagnosis was conducted in stool samples except otherwise indicated.

![](pntd.0008419.t001){#pntd.0008419.t001g}

  Country                                        Surveyed population                          Clinical manifestations                                              Diagnostic method    Prevalence (%)                                      Genotype(s)                                                                                                                         Reference
  ---------------------------------------------- -------------------------------------------- -------------------------------------------------------------------- -------------------- --------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  Cameroon                                       HIV+/TB+; HIV‒/TB+; Immunocompetent          Diarrhoea                                                            LM, IFAT             35.7 (10/28); 24.0 (6/25); 67.5 (85/126)            ND                                                                                                                                  \[[@pntd.0008419.ref016]\]
                                                 HIV‒; HIV+                                   NS                                                                   IFAT, PCR            2.9 (22/758); 0.5 (4/758)                           A (8), B (3), CAF4 (5), D (3), Type IV[^c^](#t001fn004){ref-type="table-fn"} (1)                                                    \[[@pntd.0008419.ref036]\]
                                                 HIV+ (adults)                                Diarrhoea, asymptomatic                                              LM, PCR-RFLP         6.5 (3/46); 4.6 (5/108)                             Type IV (4)                                                                                                                         \[[@pntd.0008419.ref039]\]
                                                 HIV‒                                         None                                                                 PCR                  2.6 (5/196)                                         CAF1[^d^](#t001fn005){ref-type="table-fn"} (1), Type IV (4)                                                                         \[[@pntd.0008419.ref051]\]
  Chad                                           HIV+[^a^](#t001fn002){ref-type="table-fn"}   Diarrhoea                                                            LM, IFAT, PCR        100 (1/1)                                           ND                                                                                                                                  \[[@pntd.0008419.ref052]\]
  Democratic Republic of the Congo               HIV+ (\> 15 yrs.)                            Diarrhoea                                                            PCR                  7.8 (19/242)                                        D (1), CAF1[^d^](#t001fn005){ref-type="table-fn"} (1), KIN-2 (1), KIN-3 (1), NIA1 (1)                                               \[[@pntd.0008419.ref053]\]
                                                 AIDS patients (\> 15 yrs.)                   Diarrhoea                                                            IFAT, PCR            5.1 (9/175)                                         NIA1 (2)                                                                                                                            \[[@pntd.0008419.ref054]\]
                                                 AIDS patients                                Diarrhoea, other                                                     LM, IFAT,            2.0 (1/50)                                          ND                                                                                                                                  \[[@pntd.0008419.ref055]\]
  Democratic Republic of São Tome and Principe   Rural children; Urban inpatient children     Diarrhoea, other                                                     PCR                  5.2 (7/134); 8.9 (19/214)                           CAF1[^d^](#t001fn005){ref-type="table-fn"} (4), KIN-3 (1), Type IV (14), A (2), D (5)                                               \[[@pntd.0008419.ref030]\]
  Ethiopia                                       HIV+, HIV‒ (adults)                          Diarrhoea                                                            U2B, PCR             14.3 (15/105)                                       ND                                                                                                                                  \[[@pntd.0008419.ref056]\]
                                                 HIV+, HIV‒ (adults)                          Diarrhoea, other                                                     LM, PCR              12.3 (30/243)                                       ND                                                                                                                                  \[[@pntd.0008419.ref057]\]
  Gabon                                          HIV+ (\> 16 yrs.)                            Diarrhoea                                                            IFAT, PCR            3.0 (25/822)                                        A (1), CAF1 (3), CAF2 (1), CAF3 (1), CAF4 (4), D (1), Type IV[^c^](#t001fn004){ref-type="table-fn"} (4)                             \[[@pntd.0008419.ref036]\]
  Kenya                                          HIV+ (adults)                                Diarrhoea                                                            U2B                  3.0 (1/36)                                          ND                                                                                                                                  \[[@pntd.0008419.ref058]\]
  Madagascar                                     Inpatients (adults)                          Diarrhoea, asymptomatic                                              PCR                  1.5 (1/67); 2.5 (5/198)                             ND                                                                                                                                  \[[@pntd.0008419.ref059]\]
  Malawi                                         HIV+, HIV‒                                   NS                                                                   PCR                  100 (37/37)[^b^](#t001fn004){ref-type="table-fn"}   D (4), Type IV[^c^](#t001fn004){ref-type="table-fn"} (9), Peru8 (1), S1 (1), S2 (11), S3 (2), S4 (1), S5 (4), S6 (2), UG2145 (1),   \[[@pntd.0008419.ref035]\]
                                                 HIV+ (\< 18 yrs.)                            Diarrhoea, other                                                     qPCR                 37.0 (13/35)                                        ND                                                                                                                                  \[[@pntd.0008419.ref007]\]
  Mali                                           HIV+ (adults); HIV‒ (adults)                 Diarrhoea                                                            TEM, LM              32.0 (28/88); 27.0 (3/11)                           ND                                                                                                                                  \[[@pntd.0008419.ref060]\]
                                                 HIV+ Immunocompetent children                Diarrhoea                                                            U2B, IFAT, PCR       14.8 (9/61); 0.0 (0/71)                             ND                                                                                                                                  \[[@pntd.0008419.ref061]\]
  Mozambique                                     Children and adults                          Asymptomatic                                                         PCR                  9.0 (27/301)                                        ND                                                                                                                                  \[[@pntd.0008419.ref027]\]
                                                 Children                                     Diarrhoea, asymptomatic                                              PCR                  0.3 (1/331); 0.9 (8/916)                            HhMzEb1 (4), Peru11 (1), Type IV (2), S2 (2)                                                                                        This study
  Niger                                          HIV+ (Adults); HIV‒ (children)               Diarrhoea, other                                                     TEM, LM              7.0 (4/60); 0.8 (8/990)                             ND                                                                                                                                  \[[@pntd.0008419.ref062]\]
                                                 HIV+ (mostly adults)                         NS                                                                   LM, qPCR             10.5 (24/228)                                       A (10), CAF1 (2), D (2), E (1), HAN1 (1) Type IV[^c^](#t001fn005){ref-type="table-fn"} (1), NIA1 (3)                                \[[@pntd.0008419.ref041]\]
  Nigeria                                        Rural/urban dwellers                         NS                                                                   LM                   39.6 (80/204)                                       ND                                                                                                                                  \[[@pntd.0008419.ref017]\]
                                                 HIV‒ (children)                              Diarrhoea, asymptomatic                                              PCR                  9.3 (4/43)                                          D (2), Type IV[^c^](#t001fn004){ref-type="table-fn"} (1), novel K-like (1)                                                          \[[@pntd.0008419.ref031]\]
                                                 HIV+, HIV‒                                   Diarrhoea, other                                                     PCR                  6.4 (10/157)                                        A/Type IV (1), D (3), D/WL7 (1), Type IV (1), WL7 (3), WL7/Type IV (1)                                                              \[[@pntd.0008419.ref042]\]
                                                 HIV+ (adults)                                Diarrhoea, other                                                     PCR                  26.5 (26/98); 4.3 (52/365)                          A (22), CAF2 (2), D (31), D/Type IV (1), EbpA (1), Type IV (14), Nig1(1), Nig2 (1), Nig3 (1), Nig4 (1), Nig5 (1), Peru8 (1)         \[[@pntd.0008419.ref043]\]
                                                 HIV+                                         Diarrhoea                                                            PCR                  7.7 (10/132)                                        D (1), Nig2 (2), Peru8 (1), Nig4-like (1), Type IV (5)                                                                              \[[@pntd.0008419.ref063]\]
                                                 HIV+ (adults on HAART)                       Diarrhoea, asymptomatic                                              PCR                  11.1 (12/108); 3.4 (6/177)                          Mixed genotypes (3), Nig4 (2), Nig6 (10), Nig7 (2), Type IV (1)                                                                     \[[@pntd.0008419.ref064]\]
                                                 HIV+                                         Diarrhoea, asymptomatic                                              LM, IFAT, PCR        2.6 (5/193)                                         B (1), P-like, Peru3, PtEb IV, PtEb V, Type IV, UG2145 (2)                                                                          \[[@pntd.0008419.ref065]\]
                                                 HIV+ (adults)                                Diarrhoea                                                            PCR                  5.5 (5/90)                                          Type IV (4), unknown mixed infection (1)                                                                                            \[[@pntd.0008419.ref066]\]
  South Africa                                   HIV+ (inpatients); HIV‒ (children)           Diarrhoea                                                            LM, PCR-RFLP, qPCR   12.9 (33/255); 4.5 (3/67)                           ND                                                                                                                                  \[[@pntd.0008419.ref032]\]
  Tanzania                                       HIV+ (adults); HIV+, HIV‒(children)          Diarrhoea, other; Chronic diarrhoea; Acute diarrhoea; Asymptomatic   LM, TEM              3.5 (3/86); 3.4 (2/59); 0.0 (0/55); 20.0 (4/20)     ND                                                                                                                                  \[[@pntd.0008419.ref034]\]
  Tunisia                                        Immunocompromised patients                   Diarrhoea                                                            LM, PCR              3.5 (3/86)                                          ND                                                                                                                                  \[[@pntd.0008419.ref067]\]
                                                 HIV+ (newborn)                               Asymptomatic                                                         LM, PCR              100 (1/1)                                           ND                                                                                                                                  \[[@pntd.0008419.ref068]\]
                                                 HIV+ (adults); HIV‒ (adults)                 Diarrhoea, other                                                     LM, PCR              20.0 (7/35); 5.3 (3/56)                             ND                                                                                                                                  \[[@pntd.0008419.ref069]\]
                                                 HIV+ (adults)                                Diarrhoea                                                            LM, PCR              2.5 (3/119); 5.9 (7/119)                            ND                                                                                                                                  \[[@pntd.0008419.ref070]\]
                                                 HIV+ (mostly adults)                         Diarrhoea                                                            LM, PCR              100% (7/7)                                          B (2), D (4), Peru8 (1)                                                                                                             \[[@pntd.0008419.ref071]\]
                                                 HIV+ (adults)                                Diarrhoea, asymptomatic                                              LM, PCR              19.4 (6/31); 2.8 (2/71)                             ND                                                                                                                                  \[[@pntd.0008419.ref072]\]
  Uganda and Zambia                              HIV+[^b^](#t001fn003){ref-type="table-fn"}   Diarrhoea, other                                                     LM, TEM              6.5 (5/77)                                          ND                                                                                                                                  \[[@pntd.0008419.ref073]\]
                                                 Children (\< 5 yrs)                          Diarrhoea, asymptomatic                                              LM, PCR              17.4 (310/1779); 16.8 (112/667)                     Type IV[^c^](#t001fn004){ref-type="table-fn"} (6), UG2145 (1)                                                                       \[[@pntd.0008419.ref040]\]
                                                 HIV+ (children); HIV‒ (children)             Diarrhoea, other                                                     PCR                  76.9 (70/91); 6.6 (10/152)                          ND                                                                                                                                  \[[@pntd.0008419.ref033]\]
  Zambia                                         Rural children                               Asymptomatic                                                         U2B, TEM             0.6 (1/176)                                         ND                                                                                                                                  \[[@pntd.0008419.ref074]\]
  Zimbabwe                                       HIV+ (adults)                                Diarrhoea                                                            LM                   10.0 (13/129)                                       ND                                                                                                                                  \[[@pntd.0008419.ref075]\]
                                                 HIV+ (adults)                                Diarrhoea                                                            LM, PCR              46.0 (34/74)                                        ND                                                                                                                                  \[[@pntd.0008419.ref076]\]
                                                 HIV+ (adults)                                Diarrhoea                                                            LM, PCR              18.0 (10/55); 51.0 (28/55)                          ND                                                                                                                                  \[[@pntd.0008419.ref077]\]
                                                 HIV‒                                         Diarrhoea, other                                                     LM, PCR              33.0 (2/6)                                          ND                                                                                                                                  \[[@pntd.0008419.ref078]\]

HAART, Highly active antiretroviral therapy; HIV, Human immunodeficiency virus; IFAT, immunofluorescence antibody test; LM, light microscopy; ND, not determined; NS, not specified; PCR, polymerase chain reaction; qPCR, real-time PCR; RFLP, restriction fragment length polymorphism; TB, Tuberculosis; TEM, Transmission electron microscopy; U2B, Uvitex 2B fluorescent dye.

^a^ Patient from Chad diagnosed in France.

^b^ Diagnosed in an intestinal biopsy.

^c^ Reported as genotype K.

^d^ Reported as genotype KIN-1.

Methods {#sec002}
=======

Ethics statement {#sec003}
----------------

Written informed consent was obtained from legal guardians of children voluntarily participating in this survey. All procedures involved in the study were approved by the Ethics Committee of the Health Institute Carlos III under reference number CEI PI 17_2017-v3, and the National Bioethics Committee for Health (CNBS--Comité Nacional de Bioética para Saúde) of Mozambique under reference number 52/CNBS/2017 (participants in Zambézia). Similarly, approval by the Centro de Investigação em Saúde de Manhiça's Institutional Bioethics Committee for Health---CIBS (Ref. CIBS-CISM/075/2015), with final approval by CNBS (Ref. 209/CNBS/15), were obtained for participants in Maputo.

Study design {#sec004}
------------

This study is part of an ongoing research collaborative effort involving the Spanish National Centre for Microbiology (SNCM) in Spain, the Centro de Investigação em Saúde de Manhiça (CISM)/Fundação Manhiça (FM) in Mozambique, and the United States Department of Agriculture to assess the molecular epidemiology of the most frequent enteric protist parasites infecting humans in Mozambique. Two independent studies involving different sampling designs were conducted in Zambézia and Maputo provinces.

Collection of stool samples in Zambézia province {#sec005}
------------------------------------------------

Zambézia (population: 5.1 million; total area: 103,478 km^2^) is the second most-populous province of Mozambique, located in the central coastal region of the country. A prospective cross-sectional molecular epidemiological study was carried out between October 2017 and February 2019. All enrolled children were between 3 and 14 years old. A first set of samples were obtained from school children attending 18 public schools with each 35‒2,111 (mean: 651) children in 10 of the 22 districts of Zambézia. Voluntary participants were provided with sampling kits (sterile polystyrene plastic flask with spatula and a unique identification number) to obtain individual stool samples. In addition, a second set of samples from children presenting with gastrointestinal complaints (abdominal pain, anal pruritus, bloating, constipation, diarrhoea, flatulence, loss of appetite, nausea, vomiting) seeking medical attention in health care centres (*n* = 6) and hospital settings (*n* = 1) from six districts of the province were collected.

For both sets, an aliquot of each faecal sample was transferred to a TOTAL-FIX stool collection device (Durviz, Valencia, Spain) and shipped to SNCM in Majadahonda (Spain) for downstream molecular analyses.

Collection of stool samples in Maputo province {#sec006}
----------------------------------------------

The study in the Maputo province was conducted in the Manhiça district (population: 0.2 million; total area: 2,373 km^2^) that is located approximately 80 km north of the capital city Maputo in Southern Mozambique. The Manhiça district has been under a Health and Demographic Surveillance System (HDSS) from CISM since 1996, allowing the link between demographic and clinical data of the population \[[@pntd.0008419.ref018]\].

Stool samples were collected from children under 5 years of age under an ongoing surveillance of diarrheal diseases conducted by the CISM since September 2015 in the Manhiça District Hospital (MDH) and other health peripheral facilities \[[@pntd.0008419.ref018],[@pntd.0008419.ref019]\]. Children under 5 years of age presenting to the peripheral health facilities with moderate-to-severe and less-severe diarrhoea were recruited. Definition of diarrhoeal cases and inclusion criteria to participate in the research study were as previously described \[[@pntd.0008419.ref020]\]. In addition, starting from December 2016, 1 to 3 community controls (asymptomatic children free of diarrhoea episode \> 14 days) matched to the index case by age, sex and neighbourhood were identified (using the HDSS databases) and enrolled within 14 days after said index case was enrolled. Stools were collected for both cases and controls and sent to the laboratory for processing. Additionally, stools from children presenting to the sentinel health facility complaining with less-severe diarrhoea and those children presenting to the Xinavane Rural Hospital (XRH), were enrolled starting in April 2017 up to December 2018. Stool samples were collected in sterile flasks, transported to the laboratory, and stored at ‒80°C without any preservatives for further testing of enteric pathogens as previously described \[[@pntd.0008419.ref021]\].

Data collection {#sec007}
---------------

Epidemiological and clinical information was collected in a standardized questionnaire provided as part of the sampling kits and labelled with the same identification number. The questionnaire was completed by researchers interviewing participating children and their caretakers at the time of sampling. The questionnaire included basic demographic characteristics (age, sex, place of living), and potential risk factors including contact with livestock or companion animals, type of drinking water, and information regarding the defecation place. There were some differences between Manhiça and Zambézia questionnaires.

DNA extraction and purification {#sec008}
-------------------------------

In stool samples from Zambézia, DNA was isolated from 200 mg of faecal material using the QIAamp Fast DNA stool mini Kit and the QIAcube robot (Qiagen, Hilden, Germany) following the manufacturer\'s instructions except that treatment of the samples with the lysis buffer was carried out for 10 minutes at 95°C. Purified DNA samples (200 μL) were stored at -20 ºC for downstream molecular analysis. In Manhiça, DNA was manually extracted and purified using the QIAamp DNA Stool Mini Kit from 200 mg of faecal material following the manufacturer\'s instructions, with the same modification for the lysing step. Purified DNA samples (200 μL) were shipped to the SNCM for molecular testing.

Molecular detection of *Enterocytozoon bieneusi* {#sec009}
------------------------------------------------

To detect *E*. *bieneusi*, a nested PCR was conducted to amplify a 390-bp fragment including the entire ITS as well as portions of the flanking large and small subunit of the rRNA gene \[[@pntd.0008419.ref022]\]. Primary and secondary reactions (50 μL) were carried out using the outer primer set EBITS3 (5´‒GGTCATAGGGATGAAGAG‒3´) and EBITS4 (5´‒TTCGAGTTCTTTCGCGCTC‒3´), and the inner primer set EBITS1 (5´‒GCTCTGAATATCTATGGCT‒3´) and EBITS2.4 (5´‒ATCGCCGACGGATCCAAGTG‒3´), respectively. Reaction mixtures consisted of 1 μL of template DNA, 200 nM of each primer, 2.5 units of MyTAQ DNA polymerase (Bioline GmbH, Luckenwalde, Germany), and 5 μL of MyTAQ Reaction Buffer containing 5 mM dNTPs and 15 mM MgCl~2~. Cycling conditions for the primary PCR were as follows: after denaturation at 94°C for 3 min, samples were subjected to 35 cycles of amplification (denaturation at 94°C for 30 s, annealing at 57°C for 30 s, and elongation at 72°C for 40 s), followed by a final extension at 72°C for 10 min. Conditions for the secondary PCR were identical to the primary PCR except only 30 cycles were carried out with an annealing temperature of 55°C. Negative (no DNA template) and positive (*E*. *bieneusi* PCR-positive samples, genotypes Ebcar2 and EbpA) controls were included in all PCR runs. PCR products were resolved on 2% D5 agarose gels (Conda, Madrid, Spain) stained with Pronasafe (Conda).

Sequence analysis {#sec010}
-----------------

All amplicons of the expected size were directly sequenced in both directions using the internal primer set in 10 μL reaction mixes using Big Dye chemistries and an ABI 3730xl sequencer analyser (Applied Biosystems, Foster City, CA). Sequencing data were viewed using Chromas Lite version 2.1 software (<https://technelysium.com.au/wp/chromas/>) to generate consensus sequences. The Blast tool (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) was used to compare those sequences with reference sequences deposited at the National Center for Biotechnology Information (NCBI). *Enterocytozoon bieneusi* genotypes were determined using the established nomenclature system based on ITS nucleotide sequence \[[@pntd.0008419.ref014]\]. Sequences obtained in the present study were deposited in the GenBank database under accession numbers MN845065 to MN845068.

Phylogenetic analysis {#sec011}
---------------------

Nucleotide sequences obtained in this study and *E*. *bieneusi* nucleotide sequences for all genotypes previously identified in human and animals in Africa as well as appropriate reference sequences to include all *E*. *bieneusi* groups retrieved from GenBank were aligned with the Clustal W algorithm using MEGA X \[[@pntd.0008419.ref023]\]. Phylogenetic inference was carried out by the Neighbor-Joining (NJ) method as previously described \[[@pntd.0008419.ref024]\], genetic distance was calculated with the Kimura parameter-2 model using MEGA X \[[@pntd.0008419.ref023]\].

Statistical analysis {#sec012}
--------------------

We analysed the data using EpiData 4.2.0 (EpiData Association, Odense, Denmark) and Stata software, versions 15 (STATA Corp., College Station, Texas, US). We calculated odds ratios (OR) for associations; a probability (*P*) value \< 0.05 was considered evidence of statistical significance. We examined for possible confounders (change of \> 20% in OR) and interactions. As both populations included selection by symptomatic and asymptomatic populations, we included "a priori" the symptomatic variable in the multivariable model. As the event was rare, and some factors (e.g. *G*. *duodenalis*) were found in all cases, we used a penalised regression (Firth regression) selecting risk factors with a *P*-value ≤ 0.2 from the univariable analysis, using Akaike\'s information criterion (AIC) and Bayesian information criterion (BIC) to determine selection and evaluate the final model \[[@pntd.0008419.ref025]\].

Results {#sec013}
=======

A total of 1,247 children aged between 0 and 14 years-old were recruited to participate in this study in the Manhiça District in Maputo (*n* = 150) and Zambézia province (*n* = 1,097) in Mozambique. The main socio-demographic and epidemiological features of these paediatric populations are summarized in [Table 2](#pntd.0008419.t002){ref-type="table"}.

10.1371/journal.pntd.0008419.t002

###### Main socio-demographic and epidemiological features, expressed as frequencies, of the Mozambican children populations (*n* = 1,247) investigated in the present study.

![](pntd.0008419.t002){#pntd.0008419.t002g}

                                   Zambézia                                     Manhiça district--Maputo                                                                                                                                          
  -------------------------------- -------------------------------------------- -------------------------- -------------------------------------------- -------------------------------------------- -------------------------------------------- --------------------------------------------
  **Gender**                                                                                                                                                                                                                                      
      Male                         49.7                                         50.3                       49.9                                         54.1                                         48.8                                         52.7
      Female                       50.3                                         49.7                       50.1                                         45.9                                         51.2                                         47.3
  **Age group (years)**                                                                                                                                                                                                                           
      0‒5                          13.4                                         33.8                       18.8                                         100                                          100                                          100
      6‒10                         64.3                                         49.3                       60.3                                         NA                                           NA                                           NA
      11‒14                        22.3                                         16.9                       20.9                                         NA                                           NA                                           NA
  **Area**                                                                                                                                                                                                                                        
      Rural                        86.5                                         43.8                       75.2                                         100                                          100                                          100
      Urban                        13.5                                         56.2                       24.8                                         NA                                           NA                                           NA
  **Contact with livestock**                                                                                                                                                                                                                      
      Yes                          4.6                                          14.1                       7.1                                          59[^b^](#t002fn003){ref-type="table-fn"}     46.3[^c^](#t002fn004){ref-type="table-fn"}   55.3[^b^](#t002fn003){ref-type="table-fn"}
      No                           95.4                                         85.9                       92.9                                         41[^b^](#t002fn003){ref-type="table-fn"}     53.7[^c^](#t002fn004){ref-type="table-fn"}   44.7[^b^](#t002fn003){ref-type="table-fn"}
  **Contact with dogs/cats**                                                                                                                                                                                                                      
      Yes                          18.8                                         26.6                       20.9                                         30[^b^](#t002fn003){ref-type="table-fn"}     19.5[^c^](#t002fn004){ref-type="table-fn"}   26.9[^b^](#t002fn003){ref-type="table-fn"}
      No                           81.2                                         73.4                       79.1                                         70[^b^](#t002fn003){ref-type="table-fn"}     80.5[^c^](#t002fn004){ref-type="table-fn"}   73.1[^b^](#t002fn003){ref-type="table-fn"}
  **Main drinking water source**                                                                                                                                                                                                                  
      River/springs                4.3[^a^](#t002fn002){ref-type="table-fn"}    4.1                        4.3[^a^](#t002fn002){ref-type="table-fn"}    2[^b^](#t002fn003){ref-type="table-fn"}      2.4                                          3.6[^b^](#t002fn003){ref-type="table-fn"}
      Tap                          23.2[^a^](#t002fn002){ref-type="table-fn"}   54.1                       31.4[^a^](#t002fn002){ref-type="table-fn"}   91[^b^](#t002fn003){ref-type="table-fn"}     80.5                                         86.5[^b^](#t002fn003){ref-type="table-fn"}
      Well                         72.0[^a^](#t002fn002){ref-type="table-fn"}   41.7                       64.0[^a^](#t002fn002){ref-type="table-fn"}   7[^b^](#t002fn003){ref-type="table-fn"}      17.1                                         9.9[^b^](#t002fn003){ref-type="table-fn"}
  **Defecation place**                                                                                                                                                                                                                            
      Latrine                      88.0                                         76.9                       85.1                                         100 [^c^](#t002fn004){ref-type="table-fn"}   100 [^d^](#t002fn005){ref-type="table-fn"}   100 [^e^](#t002fn006){ref-type="table-fn"}
      Outside                      12.0                                         23.1                       14.9                                         0.0 [^c^](#t002fn004){ref-type="table-fn"}   0.0 [^d^](#t002fn005){ref-type="table-fn"}   0.0 [^e^](#t002fn006){ref-type="table-fn"}

NA: not applicable.

^a^ Information for four children was not available.

^b^ Information for nine children was not available.

^c^ Information for one child was not available.

^d^ Information for five children was not available.

^e^ Information for six children was not available.

In Zambézia, 807 asymptomatic schoolchildren and 290 children presenting with gastrointestinal complaints seeking for medical care were investigated in 10 and six districts of the province, respectively ([Table 2](#pntd.0008419.t002){ref-type="table"} and [S1](#pntd.0008419.s002){ref-type="supplementary-material"} and [S2](#pntd.0008419.s003){ref-type="supplementary-material"} Tables). The overall male/female ratio was 1.0, and children in the age group 6 to 10 years-old represented 60% of the surveyed individuals. Three out of four children investigated lived in rural areas.

In the rural Manhiça district, 109 asymptomatic children and 41 children presenting with gastrointestinal complaints (11 with moderate-to-severe diarrhoea and 30 with less severe diarrhoea) and seeking for medical care were investigated ([Table 2](#pntd.0008419.t002){ref-type="table"} and [S3](#pntd.0008419.s004){ref-type="supplementary-material"} and [S4](#pntd.0008419.s005){ref-type="supplementary-material"} Tables). In this subpopulation, the male/female ratio was 1.1, and children in the age group 12--23 months-old represented 40.7% of the surveyed individuals. Most children (62.7%) were from the area covered by the MDH. All these children lived in rural areas.

Overall, *E*. *bieneusi* was detected by nested-PCR and confirmed by sequencing in 0.7% (9/1,247, 95% CI: 0.4--1.4) of the investigated children population. The prevalence was more than 10-fold higher in the Manhiça district in Maputo (4.0%, 6/150, 95% CI: 1.8--8.6) compared to all the districts in Zambézia combined (0.3%, 3/1,097, 95%CI: 0.1--0.8). The prevalence for those without symptoms was 0.9% (8/916, 95% CI: 0.4--1.7) and for those with symptoms 0.3% (1/331, 95% CI: 0.04--2.1), and those with diarrhoea 0.4% (1/251, 95% CI: 0.06--2.8). Nucleotide sequences of the ITS revealed the presence of four distinct *E*. *bieneusi* genotypes, three previously reported in humans (Type IV, S2, and Peru11) and a novel genotype (named HhMzEb1). No mixed infections were observed. Novel genotype HhMzEb1 differed from genotype D (AF101200) by one nucleotide. Genotype S2 nucleotide sequence obtained in this study showed a SNP at the large subunit region when compared with reference sequence (GenBank accession number FJ439678).

The main socio-demographic, epidemiological, and genotypes identified in each of the *E*. *bieneusi* infections identified in the present study are shown in [Table 3](#pntd.0008419.t003){ref-type="table"}. In the Zambézia province, *E*. *bieneusi* was found in 3 asymptomatic children. Two of them lived in a rural area, attended the same school, but were infected by different genotypes (Peru11 and S2) of the parasite. Both children were co-infected with *G*. *duodenalis*, *Blastocystis* sp., and *Strongyloides* spp. The third child was infected by the Type IV genotype of *E*. *bieneusi* and was co-infected with *G*. *duodenalis*. None of the symptomatic children investigated in this province tested positive to *E*. *bieneusi*.

10.1371/journal.pntd.0008419.t003

###### Main socio-demographic features, risk factors, and genotyping data of Mozambican children positive to *Enterocytozoon bieneusi* (*n* = 9) in the present study.

![](pntd.0008419.t003){#pntd.0008419.t003g}

  Province   District       Sample ID                                                                                                                             Area    Gender   Age              Contact with livestock and/or poultry   Contact with companion animals   Main source of drinking water   Defecation place   Genotype                                        GenBank accession number
  ---------- -------------- ------------------------------------------------------------------------------------------------------------------------------------- ------- -------- ---------------- --------------------------------------- -------------------------------- ------------------------------- ------------------ ----------------------------------------------- --------------------------
  Zambézia   Gurúe          18                                                                                                                                    Urban   Male     132 months-old   No                                      Cat, dog                         Public tap                      Latrine            Type IV                                         MN845065
             Mocuba         207                                                                                                                                   Rural   Male     60 months-old    No                                      No                               Well                            Outside            Peru11                                          MN845067
             Mocuba         210                                                                                                                                   Rural   Female   60 months-old    No                                      No                               Well                            Outside            S2                                              MN845066
  Maputo     Manhiça--MDH   1728661.9[^a^](#t003fn002){ref-type="table-fn"}^,^ [^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}   Rural   Male     16 months-old    Poultry                                 No                               Public tap                      Latrine            HhMzEb1[^b^](#t003fn003){ref-type="table-fn"}   MN845068
             Manhiça--MDH   1725028.3                                                                                                                             Rural   Male     28 months-old    ND                                      ND                               ND                              Latrine            HhMzEb1[^b^](#t003fn003){ref-type="table-fn"}   Identical to MN845068
             Manhiça--XRH   1754917.2[^e^](#t003fn006){ref-type="table-fn"}                                                                                       Rural   Male     16 months-old    ND                                      ND                               ND                              Latrine            HhMzEb1[^b^](#t003fn003){ref-type="table-fn"}   Identical to MN845068
             Manhiça--XRH   1725031.3[^d^](#t003fn005){ref-type="table-fn"}^,^[^e^](#t003fn006){ref-type="table-fn"}                                              Rural   Male     12 months-old    No                                      No                               Public tap                      Latrine            Type IV                                         Identical to MN845065
             Manhiça--XRH   1754898.4                                                                                                                             Rural   Male     12 months-old    Goat, poultry                           No                               Unprotected well                Latrine            S2                                              Identical to MN845066
             Manhiça--MDH   1754369.9[^f^](#t003fn007){ref-type="table-fn"}                                                                                       Rural   Male     15 months-old    No                                      No                               ND                              Latrine            HhMzEb1[^b^](#t003fn003){ref-type="table-fn"}   Identical to MN845068

ND: no data available; MDH: Manhiça District Hospital; XRH: Xinavane Rural Hospital.

^a^ Symptomatic child presenting with moderate-to-severe diarrhoea.

^b^ Novel genotype.

^c^ Co-infected with *Cryptosporidium meleagridis* and HIV positive.

^d^ Deceased.

^e^ Co-infected with Rotavirus.

^f^ Co-infected with *Cryptosporidium parvum*.

In Maputo province, *E*. *bieneusi* was found in six male children, one presenting with moderate-to-severe diarrhoea and 5 asymptomatic. Five out of the six cases were younger than 2 years old. The S2 and Type IV genotypes were found in a single boy each, one of them co-infected with Rotavirus. Among the 4 boys infected with the novel genotype, HhMzEb1, one was HIV positive, presented with moderate-to-severe diarrhoea, and was co-infected with *Cryptosporidium meleagridis*. Another boy with this genotype was co-infected with *C*. *parvum*, and a third one was co-infected with Rotavirus. All six *E*. *bieneusi*-positive samples were co-infected with *G*. *duodenalis*.

Univariable analysis ([Table 4](#pntd.0008419.t004){ref-type="table"}) of the combined data showed that significant risk associations included infections with *G*. *duodenalis* or *Cryptosporidium* spp. and age, but handwashing was protective. In the Zambézia dataset alone, *G*. *duodenalis* was a significant association. In addition, travel, *Blastocystis* sp., and absence of a latrine were associated with presence of *E*. *bieneusi* (*P* value \< 0.5), but confidence intervals crossed 1, with only 3 positive cases. In the Maputo dataset there were no significant associations. In the final multivariable model using the combined dataset, after adjusting for symptoms, the risk associations for *E*. *bieneusi* were infection with *G*. *duodenalis* \[OR: 19.11, *P* = 0.43, 95% CI (1.10--332.94)\]; infection with *Cryptosporidium* spp. \[OR 5.75, *P* = 0.49 95% CI (1.01--32.89)\] and handwashing \[OR 0.31 P = 0.128 95%CI (0.67--1.41)\]. Although handwashing was not significant, it was retained in the final model as it confounded the relationship with *Cryptosporidium* spp. Age was not a factor after adjustment for other variables.

10.1371/journal.pntd.0008419.t004

###### Descriptive and univariable analysis of the variables of interest potentially associated with an increased exposure risk to *Enterocytozoon bieneusi* in the present study.
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  Variable                       Cases of *E*. *bieneusi* with variable   \%    Non cases with variable   \%     Odds ratio   95% CI        *P* value
  ------------------------------ ---------------------------------------- ----- ------------------------- ------ ------------ ------------- -----------
  *Cryptosporidium* spp.         2                                        22    35                        3      9.82         0.96--53.84   0.001
  *Giardia duodenalis*           9                                        100   556                       45     15.27        2.87--.       0.001
  Age                            Continuous                                                               0.66   0.51--0.85   0.001         
  Handwashing (yes)              6                                        67    1152                      93     0.14         0.03--0.86    0.001
  Male Sex                       7                                        78    622                       50     3.47         0.66--34.29   0.1
  Has livestock                  2                                        22    150                       12     3.61         0.32--25.37   0.115
  Water source (not tap water)   3                                        33    885                       71     0.39         0.05--2.94    0.236
  Symptomatic                    1                                        11    330                       27     0.34         0.01--2.58    0.293
  *Blastocystis* sp.             2                                        22    156                       13     1.98         0.20--10.51   0.387
  No latrine                     2                                        22    162                       13     1.89         0.19--10.01   0.423
  Rural                          8                                        89    967                       78     2.24         0.30--99.83   0.435
  Has pets (dog/cats)            1                                        11    267                       22     0.72         0.02--6.50    0.766
  *Stronglyloides stercoralis*   2                                        22    253                       20     1.11         0.11--5.88    0.895
  *Entamoeba dispar*             1                                        11    122                       10     1.14         0.03--8.65    0.9

95% CI: 95% Confidence Interval.

Phylogenetic analysis revealed that the novel genotype HhMzEB1 clustered within Group 1 when its relationship with other genotypes of human and animal origin previously reported in Africa was evaluated ([Fig 1](#pntd.0008419.g001){ref-type="fig"}).

![Phylogenetic relationships among *Enterocytozoon bieneusi* genotypes identified in this study.\
All genotypes identified in humans and animals in Africa, and genotypes to cover all groups of *E*. *bieneusi* were included for comparative purposes. Analyses were inferred by a Neighbor-Joining method of the entire ITS of rRNA gene based on genetic distances calculated by the Kimura two-parameter model (MEGA X software). All nucleotide sequences include host information with the GenBank accession number in parenthesis. Nucleotide sequences determined in this study are identified with black circles before the genotype name. White circles indicate genotypes identified in Africa.](pntd.0008419.g001){#pntd.0008419.g001}

Discussion {#sec014}
==========

Little information is currently available on the occurrence and distribution of enteric parasites in Mozambique \[[@pntd.0008419.ref026]--[@pntd.0008419.ref028]\], although the GEMS project has significantly improved our understanding of the epidemiology of diarrhoea-associated with parasites *G*. *duodenalis*, *Cryptosporidium* spp., and *E*. *histolytica* \[[@pntd.0008419.ref015], [@pntd.0008419.ref029]\]. However, there is almost no information regarding Microsporidia, and only one study that aimed to investigate the prevalence of intestinal parasite infections in an informal settlement in Beira, Mozambique has reported *E*. *bieneusi* \[[@pntd.0008419.ref027]\]. They detected *E*. *bieneusi* by real-time PCR in 9.3% (28/301) of the individuals tested and no genotyping was provided. Therefore, this is to our knowledge the first molecular epidemiological study describing occurrence and genetic diversity of *E*. *bieneusi* in Mozambique. The overall prevalence of *E*. *bieneusi* infection in the paediatric (0‒14 years of age) populations from Mozambique tested in this study was 0.7% (9/1,247). Infections were more commonly identified in asymptomatic children in rural settings.

The *E*. *bieneusi* infection rates found in our paediatric populations in Zambézia (0.3%) and Maputo (4%) were lower than the prevalence reported in Beira in Sofala province (9%) \[[@pntd.0008419.ref027]\], indicating potential differences in the geographical distribution of the parasite in Mozambique. The disparity could also be associated with differences in socioeconomic characteristics of the studied population as the study in Beira was conducted in an informal settlement in an area that is frequently flooded and not connected to a sewage system after a local hospital noticed high number of diarrhoea cases in this settlement. Prevalence in Mozambique (0.7%) is lower to those previously documented in immunocompetent children populations (range: 4‒9%) in other African countries including the Democratic Republic of São Tomé and Principe \[[@pntd.0008419.ref030]\], Nigeria \[[@pntd.0008419.ref031]\], South Africa \[[@pntd.0008419.ref032]\], and Uganda \[[@pntd.0008419.ref033]\], and much lower than those found in similar paediatric populations (range: 20‒67%) in Cameroon \[[@pntd.0008419.ref016]\], Nigeria \[[@pntd.0008419.ref017]\], and Tanzania \[[@pntd.0008419.ref034]\] (see [Table 1](#pntd.0008419.t001){ref-type="table"}). However, prevalence is influenced by the age group selected in the study and the presence of symptoms, so comparisons among studies must keep those differences in mind.

It is noteworthy to indicate that all *E*. *bieneusi*-positive children were also co-infected by other pathogens including two children in Manhiça that were HIV-positive. Indeed, one to three additional enteric parasites (*G*. *duodenalis*, *Cryptosporidium* spp., *Blastocystis* sp., and *Strongyloides* spp.) were found and the strongest risk associations were with *G*. *duodenalis* and *Cryptosporidium* spp. These data clearly depict a highly endemic scenario where polyparasitism is common as previously reported in the city of Beira \[[@pntd.0008419.ref027]\].

Our study is limited by the small number of positive samples, thus the wide confidence intervals for our results. Furthermore, detailed information on handwashing (use of soap or not) and latrine use (toilet or outside latrine) were unavailable in the Zambézia dataset, and missing values for water source and animal livestock in the Maputo dataset implied limited exploration of these associations, especially given the low numbers of cases.

Nucleotide sequence analysis on the ITS region of the nine positive cases revealed the presence of four genotypes, three previously reported (Peru11, Type IV, and S2) and a novel genotype (named HhMzEb1). This constitutes the first report of these genotypes in Mozambique. Genotypes Type IV and S2 were both identified in Zambézia and Maputo, while Peru11 was only identified in Zambézia and novel genotype HhMzEb1 only in Maputo. All genotypes identified in the present study, including novel HhMzEb1, belonged to Group 1 ([Fig 1](#pntd.0008419.g001){ref-type="fig"}) that includes *E*. *bieneusi* genotypes with low host specificity that are found not only in humans but also in domestic and wild animals worldwide \[[@pntd.0008419.ref010],[@pntd.0008419.ref011],[@pntd.0008419.ref014]\]. This is the second report of genotype S2 in humans, that had only been previously reported in Malawi from three children (2 HIV-positive and one HIV-negative) and eight HIV-positive adults \[[@pntd.0008419.ref035]\]. Genotype Type IV (also reported previously as K, Peru2, BEB5, CMITS1, BEB-var, PtEB III) has widely been found in humans in different regions throughout the world \[[@pntd.0008419.ref005],[@pntd.0008419.ref036]--[@pntd.0008419.ref038]\], with multiple reports in African countries that include Gabon \[[@pntd.0008419.ref036]\], Cameroon \[[@pntd.0008419.ref036],[@pntd.0008419.ref039]\], Uganda \[[@pntd.0008419.ref040]\], Niger \[[@pntd.0008419.ref041]\], Nigeria \[[@pntd.0008419.ref031],[@pntd.0008419.ref042],[@pntd.0008419.ref043]\], Democratic Republic of São Tomé and Principe \[[@pntd.0008419.ref030]\], and Malawi \[[@pntd.0008419.ref035]\] ([S5 Table](#pntd.0008419.s006){ref-type="supplementary-material"}). In addition, Type IV has also been reported in a wide range of animal hosts including non-human primates, cattle, cats, dogs, rodents, birds, snakes, and black bears ([S5 Table](#pntd.0008419.s006){ref-type="supplementary-material"}) as well as in water samples \[[@pntd.0008419.ref044]--[@pntd.0008419.ref047]\]. There are no previous reports of Peru11 (also reported previously as Peru12) in humans in Africa, but it has been found in humans in Asia and South America ([S5 Table](#pntd.0008419.s006){ref-type="supplementary-material"}). In Africa, Peru11 has been found in a baboon in Kenya \[[@pntd.0008419.ref048]\]. In addition, there are also reports of this genotype in other parts of the world in non-human primates, cats, raccoons, rabbits, rodents, and birds ([S5 Table](#pntd.0008419.s006){ref-type="supplementary-material"}).

In this study, no mixed infections by different *E*. *bieneusi* genotypes were noticed using ITS-PCR and Sanger sequencing. However, it should be noted that co-infections seem a common finding in human populations in endemic areas. Indeed, intra-isolate diversity has been demonstrated in children with diarrhoea in Uganda using microsatellite markers (in addition to ITS) and subsequent cloning and sequencing of PCR products \[[@pntd.0008419.ref049]\]. These data preclude us to conclusively state that mixed infections are not present in the surveyed Mozambican population as the methodology used in this study was not chosen to address mixed infections. The identification of potentially zoonotic genotypes Peru11 and Type IV, commonly found not only in humans but also in domestic and wild animals worldwide, indicates the potential for zoonotic or cross-species transmission. There are few studies in the African continent that include molecular characterization of *E*. *bieneusi* in humans and in animals. However, environmental (water) samples should be also considered as a source of infection by microsporidia, as *E*. *bieneusi* has been demonstrated to be involved in waterborne outbreaks of gastrointestinal disease \[[@pntd.0008419.ref050]\]. Our findings emphasize the need of further studies to explore risk associations as these were limited in our study by the low prevalence and missing information. Studies could include water as well as animals that may be in contact with human populations in Mozambique to understand the modes of transmission of *E*. *bieneusi*, and, by analogy, of other diarrhoea-causing enteric protist species.

Conclusions {#sec015}
===========

This is the first molecular study of *E*. *bieneusi* in Mozambique. The parasite was primarily found in asymptomatic children in Maputo (Manhiça district) and Zambézia province. Molecular characterization detected a novel genotype (HhMzEb1) and three known genotypes (Type IV, Peru11 and S2) in diarrheal and healthy Mozambican children. The identification of genotypes previously described in animals suggests potential zoonotic and anthroponotic transmission. There is a lack of information of *E*. *bieneusi* in the African continent in humans, animal hosts and environmental samples. Under the One Health perspective, further genotyping studies are needed to better understand the epidemiology of this parasite.

Supporting information {#sec016}
======================

###### Occurrence of *Enterocytozoon bieneusi* in humans in Africa.

Average values for symptomatic and asymptomatic individuals are represented according to reported infection rates summarized in [Table 1](#pntd.0008419.t001){ref-type="table"}.

(TIF)
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Click here for additional data file.

###### Main socio-demographic features and risk factors of the asymptomatic schoolchildren population (*n* = 807) investigated in Zambézia province (Mozambique), 2017‒2019.

(DOCX)

###### 

Click here for additional data file.

###### Main socio-demographic features and risk factors of the symptomatic schoolchildren population (*n* = 290) attended at public health centres in Zambézia province (Mozambique), 2017‒2018.

(DOCX)

###### 

Click here for additional data file.

###### Main socio-demographic features and risk factors of the asymptomatic children population (*n* = 109) investigated in Maputo province (Mozambique), 2016‒2018.

(DOCX)

###### 

Click here for additional data file.

###### Main socio-demographic features and risk factors of the symptomatic children population (*n* = 41) investigated in Maputo province (Mozambique), 2016--2018.

(DOCX)

###### 

Click here for additional data file.

###### Summary of all *Enterocytozoon bieneusi* genotypes reported in Africa including host and geographic range.

Highlighted in bold are African countries.

(DOCX)

###### 

Click here for additional data file.
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Reviewer \#1: The manuscript by Salimo Muadica et al report on an extensive survey of Enterocytozoon bieneusi infection in children in Mozambique. These studies are difficult to conduct and the authors deserve credit for surveying a relatively large number of children.
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\"Comments to the Author\":
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Reviewer \#2: (No Response)

Reviewer \#3: -Are the conclusions supported by the data presented? YES

-Are the limitations of analysis clearly described? YES

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? YES

-Is public health relevance addressed? YES

\"Comments to the Author\": (Discussion).
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Line 103. ...capable of colonizing/infecting a broad spectrum...
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Line 126. ...could be more frequent that anticipated. Despite the progress...
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Line 230. testing for enteric pathogens

Line 249. In Manhica, DNA was manually extracted and purified using the QIA....

etc.

Reviewer \#2: (No Response)

Reviewer \#3: \"Comments to the Author\":

Keywords:
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Abstract:

\- Line 33: "Enterocytozoon bieneusi (Phylum Microsporidia)". Comment: With the new classification of the Eukaryotes, in my opinion the Microsporidia (Fungi) is not a Phylum.
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Introduction:

\- Line 92: "Microsporidia comprises 200 genera and nearly 1,500 species of spore-forming parasites". Add: "Microsporidia (Fungi) comprises 200 genera and nearly 1,500 species of spore-forming parasites".

\- Lines 95-96: "causing gastrointestinal infections globally". Add: "and other disorders and pathologies such as in lung".

Reference: "del Águila C, Lopez-Velez R, Fenoy S, Turrientes C, Cobo J, Navajas R, Visvesvara GS, Croppo GP, Da Silva AJ, Pieniazek NJ. Identification of Enterocytozoon bieneusi spores in respiratory samples from an AIDS patient with a 2-year history of intestinal microsporidiosis. J Clin Microbiol. 1997, Jul; 35(7): 1862-6".

\- Lines 105-107: "Infections are acquired through ingestion of food or water contaminated with E. bieneusi spores, or through direct contact with faeces of infected persons and animals". Add: soils.

\- Lines 118-120: "GEMS included in their study enteric protozoan parasites Giardia duodenalis, Cryptosporidium spp., and Entamoeba histolytica, but not E. bieneusi". Comment: E. bieneusi is not a protozoa parasite. Add: enteric parasites, for example.

\- Line 130: "asymptomatic paediatric populations". Change for "pediatric".

Materials and Methods:

In the epigraphs "Collection of stool samples in Zambézia province" and "Collection of stool samples in the Manhiça district, Maputo province", in my opinion is confused the treatment and sample processing (lines 188-190 and lines 229-231, respectively). The authors could clarify or homogenize this step.

\- Line 243: "DNA extraction". Add: "and purification".

Results:

\- Line 328: "Overall, E. bieneusi was detected by PCR". Add: nested.

Discussion:

\- Lines 455-461: Comment: The authors should cite or comment the importance of the water transmission of the parasite for a better knowledge of the transmission pathways in the context in which the study was carried out.

Tables:

\- Table 1: Include in the table foot (legend), TEM (transmission electron microscopy).

\- Table 3: Remove in table foot "NA: not applicable", I think it is not used.

\- S3 Table: Remove in table foot "NA: not applicable", I think it is not used.

References:

\- Add: "Adl SM, Bass D, Lane CE, Lukeš J, Schoch CL, Smirnov A, Agatha S, Berney C,Brown MW, Burki F, Cárdenas P, Čepička I, Chistyakova L, Del Campo J, Dunthorn M,Edvardsen B, Eglit Y, Guillou L, Hampl V, Heiss AA, Hoppenrath M, James TY, Karnkowska A, Karpov S, Kim E, Kolisko M, Kudryavtsev A, Lahr DJG, Lara E, Le Gall L, Lynn DH, Mann DG, Massana R, Mitchell EAD, Morrow C, Park JS, Pawlowski JW, Powell MJ, Richter DJ, Rueckert S, Shadwick L, Shimano S, Spiegel FW, Torruella G, Youssef N, Zlatogursky V, Zhang Q. Revisions to the Classification, Nomenclature, and Diversity of Eukaryotes. J Eukaryot Microbiol. 2019 Jan;66(1):4-119".

\- Add: "del Águila C, Lopez-Velez R, Fenoy S, Turrientes C, Cobo J, Navajas R, Visvesvara GS, Croppo GP, Da Silva AJ, Pieniazek NJ. Identification of Enterocytozoon bieneusi spores in respiratory samples from an AIDS patient with a 2-year history of intestinal microsporidiosis. J Clin Microbiol. 1997, Jul; 35(7): 1862-6".
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**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: The apparent absence of association between diarrhea and Eb is worth reporting. Some of the conclusions should be supported by statistical tests.

Reviewer \#2: (No Response)

Reviewer \#3: The main objective of the manuscript is very interesting with promising results. In my opinion would have been interesting to investigate the presence of other species of Microsporidia (for example Encephalitozoon spp) using others complementary techniques such as staining methods or immunological techniques.

Obviously, the authors want to study only the genotypes of E. bieneusi in children in Africa (Mozambique) as main objective. But these additional techniques (staining methods or immunological techniques) could contribute to knowledge of the prevalence of other species of Microsporidia and provide us of a valuable information for this study or for new studies in the future.

I enjoyed reviewing this article. It is extensive with detailed information with a complete review of the prevalence of E. bieneusi and its genotypes in Africa. The results are interesting highlighting the description of a novel genotype. I encourage the authors to continue investigating the circulation and prevalence of this novel genotype and those already described in Africa.
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Giovanni Widmer

Reviewer \#2: No

Reviewer \#3: Yes: Dr. Fernando Izquierdo Arias.
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Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:
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23 May 2020

Dear Dr Carmena,

We are pleased to inform you that your manuscript \'First identification of genotypes of Enterocytozoon bieneusi (Microsporidia) among symptomatic and asymptomatic children in Mozambique\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Thuy Le

Guest Editor
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Todd Reynolds

Deputy Editor
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18 Jun 2020

Dear Dr Carmena,

We are delighted to inform you that your manuscript, \"First identification of genotypes of Enterocytozoon bieneusi (Microsporidia) among symptomatic and asymptomatic children in Mozambique,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief
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